Patent classifications
C07D213/22
INERT NANOCAPSULES
Compounds are presented having the formula [M.sub.4L.sub.6].X.sub.n, where M is a transition metal ion having 6 d-shell valence electrons, X is a counter ion and n is the number of counterions such that the total charge of the compound of formula (I) is zero, and wherein L is a 5-(5-bipyridin-2,2′-yl)-2,2′-bipyridine or derivative thereof. Methods of preparing the compounds and uses of the compounds to retain radiolabels are also presented.
Heterocyclic compounds and organic light emitting device using the same
The present invention relates to a novel cyclic compound represented by Formula 1, and an organic light emitting device comprising an organic material layer including the novel cyclic compound and having improved efficiency, low driving voltage, and enhanced lifetime characteristic: ##STR00001##
Metal complexes
The present invention relates to metal complexes and to electronic devices, in particular organic electroluminescent devices, containing these metal complexes.
Heteroaryl compounds as kinase inhibitor
Provided herein are compounds of formula (I) having activity on a receptor protein tyrosine kinase, wherein R.sup.1, R.sup.2, R.sup.3, A, Q, Z, X and W are set forth in the description, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof. ##STR00001##
Heteroaryl compounds as kinase inhibitor
Provided herein are compounds of formula (I) having activity on a receptor protein tyrosine kinase, wherein R.sup.1, R.sup.2, R.sup.3, A, Q, Z, X and W are set forth in the description, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof. ##STR00001##
Redox mediators as electrolyte additives for alkaline battery cells
A redox mediator-containing electrolyte incorporated into a battery cell is described. The redox mediator-containing electrolyte includes water, at least one hydroxide salt dissolved in the water, and at least one redox mediator incorporated into the water. The at least one redox mediator increases at least one of a rate capability or a cycle life of the battery cell by at least 10%. Also described are battery cells that may include a positive electrode, a negative electrode, and the redox mediator-containing electrolyte. The battery cells may further include an ion-selective material that diffuses hydroxide ions through the material at a faster rate than at least one of the redox mediators.
Redox mediators as electrolyte additives for alkaline battery cells
A redox mediator-containing electrolyte incorporated into a battery cell is described. The redox mediator-containing electrolyte includes water, at least one hydroxide salt dissolved in the water, and at least one redox mediator incorporated into the water. The at least one redox mediator increases at least one of a rate capability or a cycle life of the battery cell by at least 10%. Also described are battery cells that may include a positive electrode, a negative electrode, and the redox mediator-containing electrolyte. The battery cells may further include an ion-selective material that diffuses hydroxide ions through the material at a faster rate than at least one of the redox mediators.
Macromolecular transition metal complexes for treatment of cancer and process for their preparation
The present invention relates to macromolecular transition metal complexes, characterized by having the general formula (I), to the process for their preparation, and to bidentate and monodentate macroligands. The invention also refers to pharmaceutical compositions and medicaments containing said macromolecular transition metal complexes, and to the use of said pharmaceutical compositions, medicaments and macromolecular transition metal complexes for cancer therapy and/or cancer prevention, as antitumor agent in solid tumors, liquid tumors and/or metastases and/or as radiosensitizer agents.
Macromolecular transition metal complexes for treatment of cancer and process for their preparation
The present invention relates to macromolecular transition metal complexes, characterized by having the general formula (I), to the process for their preparation, and to bidentate and monodentate macroligands. The invention also refers to pharmaceutical compositions and medicaments containing said macromolecular transition metal complexes, and to the use of said pharmaceutical compositions, medicaments and macromolecular transition metal complexes for cancer therapy and/or cancer prevention, as antitumor agent in solid tumors, liquid tumors and/or metastases and/or as radiosensitizer agents.
METAL COMPLEXES
The present invention relates to metal complexes and to electronic devices, in particular organic electroluminescent devices, containing these metal complexes.